Developing Relaxin Peptides as Novel Therapies for Fibrosis

开发松弛素肽作为纤维化的新疗法

• 批准号: nhmrc : 1041766
• 负责人: A/Pr Chrishan Samuel
• 金额: $ 50.1万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Research Fellowships
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/developing-relaxin-peptides-therapies-fibrosis/111388
• 关键词: Developing; Relaxin; Peptides; Novel; Therapies

I am a matrix biologist determining the molecular mechanisms and novel therapeutic targets for fibrosis (tissue scarring). In particular, my research, which has a strong translational focus, is involved with elucidating the anti-fibrotic potential of the relaxin peptide-hormones (either alone or as an adjunct therapies to existing/other novel treatments) – as a means of developing therapeutic strategies for the treatment of cardiac and renal fibrosis.

我是一名基质生物学家，致力于确定纤维化（组织疤痕）的分子机制和新的治疗靶点。特别是，我的研究具有很强的转化重点，涉及阐明松弛素肽激素的抗纤维化潜力（单独使用或作为现有/其他新疗法的辅助疗法），作为开发治疗心脏和肾脏纤维化的治疗策略的一种手段。